Jorge Cortes: Olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax

Jorge Cortes, Director of the Georgia Cancer Center, shared on X about recent paper by him as first author titled “Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)” published on Taylor and Francis Online.

Authors: Jorge Cortes, Brian A. Jonas, Gary Schiller, Alice Mims, Gail J. Roboz, Andrew H. Wei, Pau Montesinos, P. Brent Ferrell, Karen WL. Yee, Pierre Fenaux, Anthony Schwarer and Justin M. Watts

“Published the experience with olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax. Small series but providing useful information for a common scenario in the clinic.”

Source: Jorge Cortes/X